Relief Therapeutics Holding AG (RLF.SW) SIX

2.72

-0.12(-4.23%)

Updated at September 08 09:06AM

Currency In CHF

Relief Therapeutics Holding AG

Address

Bâtiment F2/F3

Geneva, 1202

Switzerland

Phone

N/A

Sector

Healthcare

Industry

Biotechnology

Employees

31

First IPO Date

August 26, 2009

Key Executives

NameTitlePayYear Born
Mr. Paolo GalfettiChief Business Officer526,0571965
Mr. Jeremy Meinen CPAChief Financial Officer01989
Mr. Giorgio ReinerChief Scientific Officer01965

Description

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.